Currently available IOLs offer a wide range of options and increasing opportunities for personalized selection. The FDA approval in August 2019 of Alcon’s AcrySof IQ PanOptix trifocal IOL, the first of its kind in the U.S., further enriched the market. Although the perfect lens that satisfies all needs without compromise is not yet there, and careful case-by-case evaluation is still required, the chances of satisfying patients are much greater than in the past.
“IOL exchange is now significantly less frequent, and patients are happier. However, getting to know your patients,
Uncategorized